Evidence map›Paper›PMID 42183163›Full record

ArticleAmerican journal of nuclear medicine and molecular imaging2026

Development and evaluation of a novel deuterated fluorine-18 PET tracer for MAO-B imaging.

Chongyi Huang, Huiyi Wei, Haige Yi, Guocong Li, Weiyuan Lin, Taoqian Zhao, Yinlong Li, Steven H Liang, Hao Xu, Lu Wang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Chongyi HuangState Key Laboratory of Bioactive Molecules and Druggability Assessment, Guangdong Basic Research Center of Excellence for Natural Bioactive Molecules and Discovery of Innovative Drugs, Department of Nuclear Medicine, The First Affiliated Hospital Jinan, China.
Huiyi WeiState Key Laboratory of Bioactive Molecules and Druggability Assessment, Guangdong Basic Research Center of Excellence for Natural Bioactive Molecules and Discovery of Innovative Drugs, Department of Nuclear Medicine, The First Affiliated Hospital Jinan, China.
Haige YiState Key Laboratory of Bioactive Molecules and Druggability Assessment, Guangdong Basic Research Center of Excellence for Natural Bioactive Molecules and Discovery of Innovative Drugs, Department of Nuclear Medicine, The First Affiliated Hospital Jinan, China.
Guocong LiState Key Laboratory of Bioactive Molecules and Druggability Assessment, Guangdong Basic Research Center of Excellence for Natural Bioactive Molecules and Discovery of Innovative Drugs, Department of Nuclear Medicine, The First Affiliated Hospital Jinan, China.
Weiyuan LinState Key Laboratory of Bioactive Molecules and Druggability Assessment, Guangdong Basic Research Center of Excellence for Natural Bioactive Molecules and Discovery of Innovative Drugs, Department of Nuclear Medicine, The First Affiliated Hospital Jinan, China.
Taoqian ZhaoState Key Laboratory of Bioactive Molecules and Druggability Assessment, Guangdong Basic Research Center of Excellence for Natural Bioactive Molecules and Discovery of Innovative Drugs, Department of Nuclear Medicine, The First Affiliated Hospital Jinan, China.
Yinlong LiState Key Laboratory of Bioactive Molecules and Druggability Assessment, Guangdong Basic Research Center of Excellence for Natural Bioactive Molecules and Discovery of Innovative Drugs, Department of Nuclear Medicine, The First Affiliated Hospital Jinan, China.
Steven H LiangState Key Laboratory of Bioactive Molecules and Druggability Assessment, Guangdong Basic Research Center of Excellence for Natural Bioactive Molecules and Discovery of Innovative Drugs, Department of Nuclear Medicine, The First Affiliated Hospital Jinan, China.
Hao XuState Key Laboratory of Bioactive Molecules and Druggability Assessment, Guangdong Basic Research Center of Excellence for Natural Bioactive Molecules and Discovery of Innovative Drugs, Department of Nuclear Medicine, The First Affiliated Hospital Jinan, China.
Lu WangState Key Laboratory of Bioactive Molecules and Druggability Assessment, Guangdong Basic Research Center of Excellence for Natural Bioactive Molecules and Discovery of Innovative Drugs, Department of Nuclear Medicine, The First Affiliated Hospital Jinan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Monoamine oxidase B (MAO-B) is a key astrocytic biomarker implicated in neuro-inflammation and neurodegenerative diseases. This study reports the development and evaluation of novel fluorine-18 (

Indexed as

deuteriumFluorine-18Monoamine oxidase BPETradiometabolites

Identifiers

PMID42183163
PMCPMC13191562

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.